Method of treating amytrophic lateral sclerosis using melatonin
The present invention relates to the treatment of amyotrophic lateral sclerosis (ALS) and/or the improvement of motor function in individuals in need of such improvement using a melatonin compound or a pharmaceutical salt of the melatonin compound.
1. A method for the treatment of a patient suffering from amyotrophic lateral sclerosis, comprising administering melatonin or a pharmaceutical salt thereof in an amount of at least 300 mg to the patient.
2. The method of claim 1 , wherein said administering comprises rectal administration.
3. The method of claim 2 , wherein said rectal administration comprises administering a suppository.
4. The method of claim 1 , wherein the amount is from 300 to 600 mg.
5. The method of claim 1 , wherein the melatonin is N-acetyl-5-methoxytryptamine or a pharmaceutically acceptable salt thereof.
6. The method of claim 5 , which further comprises administering 2-amino-6-(trifluoromethoxy) benzothiazole.
7. The method of claim 5 , wherein the N-acetyl-5-methoxytryptamine or a pharmaceutically acceptable salt thereof is administered rectally with a suppository.
8. The method of claim 1 , which further comprises administering at least one compound selected from the group consisting of 2-amino-6-(trifluoromethoxy)benzothiazole, erythropoietin, magnesium, selen, creatine, an amino acid, a vitamin, a cannabinoid, an estrogen, an androgen, endothelin, orexin, GDNF, thrombopoietin, GM-CSF, G-CSF, N-acetylserotonin, and 6-methoxy-1,2,3,4-tetrahydro beta-carboline.
9. The method of claim 8 , wherein the compound is a vitamin.
10. The method of claim 9 , wherein the vitamin is at least one of vitamin A, vitamin C, vitamin D, and vitamin E.
11. The method of claim 1 , wherein the administrating comprises a suppository with at least 300 mg of the melatonin.
12. A method of improving motor function in a patient suffering from amyotrophic lateral sclerosis and impaired motor function, comprising administering melatonin or a pharmaceutical salt thereof in an amount of at least 300 mg to the patient to improve the motor function of the patient relative to the motor function of the patient before the administering.
13. The method of claim 12 , wherein said administering comprises rectal administration.
14. The method of claim 13 , wherein said rectal administration comprises administering a suppository.
15. The method of claim 12 , wherein the amount is from 300 to 600 mg.
16. The method of claim 12 , wherein the melatonin is N-acetyl-5-methoxytryptamine or a pharmaceutically acceptable salt thereof.
17. The method of claim 16 , which further comprises administering 2-amino-6-(trifluoromethoxy) benzothiazole.
18. The method of claim 16 , wherein the N-acetyl-5-methoxytryptamine or a pharmaceutically acceptable salt thereof is administered rectally with a suppository.
19. The method of claim 12 , which further comprises administering at least one compound selected from the group consisting of 2-amino-6-(trifluoromethoxy)benzothiazole, erythropoietin, magnesium, selen, creatine, an amino acid, a vitamin, a cannabinoid, an estrogen, an androgen, endothelin, orexin, GDNF, thrombopoietin, a GM-CSF compound, G-CSF, N-acetylserotonin, and 6-methoxy-1,2,3,4-tetrahydro beta-carboline.
20. The method of claim 19 , wherein the compound is a vitamin.
21. The method of claim 20 , wherein the vitamin is at least one of vitamin A, vitamin C, vitamin D, and vitamin E.
22. The method of claim 12 , wherein the administrating comprises a suppository with at least 300 mg of the melatonin.
23. The method of claim 1 , wherein the administering is for at least one year.
24. The method of claim 12 , wherein the administering is for at least one year.
25. The method of claim 1 , wherein the administering is at night.